Family planning needs: new opportunities, emergency contraception and other new technologies

Reproductive BioMedicine Online

Volumn 3, Issue 1, 2001, Pages 34-41

  d'Arcangues, Catherine ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

contraception; education; family planning; future methods; pregnancy; side effects

Indexed keywords

CENTCHROMAN; CONTRACEPTIVE AGENT; IMMUNOLOGIC AGENT; INJECTABLE CONTRACEPTIVE AGENT; MICROBICIDE; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT;

ARTICLE; CONDOM; CONTRACEPTIVE BEHAVIOR; DECISION MAKING; DRUG SELF ADMINISTRATION; EDUCATION; EMERGENCY CONTRACEPTION; FAMILY PLANNING; FEMALE CONDOM; HUMAN; INCOME; INTRAUTERINE CONTRACEPTIVE DEVICE; MALE STERILIZATION; PREGNANCY; SEXUALLY TRANSMITTED DISEASE; SPERMATOGENESIS; TRANSDERMAL DRUG DELIVERY SYSTEM; VAGINA RING;

EID: 1842761284     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61962-1     Document Type: Article

References (68)

1. Alexander, NJ, Contraceptive vaccines. Van Look, PFA, Perez-Palacios, G, (eds.) Contraceptive Research and Development 1984 to 1994, 1994, Oxford University Press, Delhi, India, 203–213.
2. Allen, S, Lindan, C, Serufilira, A, et al. Human immunodeficiency virus infection in urban Rwanda. Demographic and behavioral correlates in a representative sample of childbearing women. Journal of the American Medical Association 266 (1991), 1657–1663.
3. Alvarez-Sanchez, F, Brache, V, Jackanicz, T, et al. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception 46 (1992), 387–398.
4. Anderson, RA, Wallace, EM, Kicman, AT, et al. Comparison between testosterone enantate-induced azoospermia and oligozoospermia in a male contraceptive study IV: suppression of endogenous testicular and adrenal androgens by exogenous testosterone. Human Reproduction 8 (1997), 1657–1662.
5. Bahamondes, L, Marchi, NM, Nakagava, HM, et al. Self-administration with Uniject of the once-a-month injectable contraceptive Cyclofem. Contraception 56 (1997), 301–304.
6. Batar, I, Gbolade, BA, Wildemeersch, D, Immediate post-abortal insertion of the frameless IUD: review of current experience. European Journal of Contraception & Reproductive Health Care 5 (2000), 96–98.
7. Behre, HM, Nashan, D, Hubert, W, et al. Depot-gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. Journal of Clinical Endocrinology and Metabolism 74 (1992), 84–90.
8. Bounds, W, Female condoms. European Journal of Contraception and Reproductive Health Care 2 (1997), 113–116.
9. Bounds, W, Szarewski, A, Lowe, D, et al. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. European Journal of Obstetrics, Gynecology and Reproductive Biology 48 (1993), 123–125.
10. Buchter, D, von Eckardstein, S, von Eckardstein, A, et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. Journal of Clinical Endocrinology and Metabolism 84 (1999), 1244–1249.
11. Callahan, M, Mauck, C, Taylor, D, et al. Comparative evaluation of three TactylonTM condoms and a latex condom during vaginal intercourse: breakage and slippage. Contraception 61 (2000), 205–215.
12. Cao, X, Zhang, W, Gao, G, et al. Randomized comparative trial in parous women of the frameless Gynefix and the TCu 380A intrauterine devices: long-term experience in a Chinese family planning clinic. European Journal of Contraception & Reproductive Health Care 5 (2000), 135–140.
13. Chen, Z, Gu, Y, Liang, X, et al. Morphological observations of vas deferens occlusion by the percutaneous injection of medical polyurethane. Contraception 53 (1996), 275–279.
14. Crabbé, P, Archer, S, Benagiano, G, et al. Long-acting contraceptive agents: design of the WHO chemical synthesis programme. Steroids 41 (1983), 243–253.
15. Croxatto, HB, Salvatierra, AM, Fuentealba, B, et al. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Human Reproduction 13 (1998), 3287–3302.
16. Fraser, AS, Lacarra, M, Mishell, DR, et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 61 (2000), 131–138.
17. French, RS, Cowan, FM, Mansour, D, et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. British College of Obstetrics and Gynaecology 107 (2000), 1218–1225.
18. Gao, E, Lin, C, Gui, Y, et al. Inhibiting effects of Sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reproduction and Contraception 10 (1999), 98–105.
19. Garza-Flores, J, Fatinikun, T, Hernandez, L, et al. A pilot study on the assessment of a progesterone/estradiol sustained release as a once-a-month injectable contraceptive. Contraception 44 (1991), 45–59.
20. George, S, Jacob, M, John, TJ, et al. A case-control analysis of risk factors in HIV transmission in South India. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 14 (1997), 290–293.
21. Glasier, A, Baird, D, The effects of self-administering emergency contraception. New England Journal of Medicine 339 (1998), 1–4.
22. Harrison, PF, Rosenfield, A, Contraceptive Research and Development - Looking to the Future, 1996, National Academy Press, Washington D.C., USA, 519.
23. Hikim, AP, Lue, YH, Wang, C, et al. Posttesticular antifertility action of triptolide in the male rat: evidence for severe impairment of cauda epididymal sperm ultrastructure. Journal of Andrology 21 (2000), 431–437.
24. IUD Research Group, UNDP/UNFPA/World Bank/WHO Special Programme of Research, Development and Research Training in Human Reproduction, The TCu 380A IUD and the frameless IUD “the Flexigard”: interim three-year data from an international multicenter trial. Contraception 52 (1995), 77–83.
25. Jones, WR, Bradley, J, Judd, SJ, et al. Phase I clinical trial of a World Health Organization birth control vaccine. Lancet 1 (1988), 1295–1298.
26. Kamischke, A, Plöger, D, Venherm, S, et al. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clinical Endocrinology 53 (2000), 43–52.
27. Kamischke, A, Venherm, S, Plöger, D, et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. Journal of Clinical Endocrinology and Metabolism 86 (2001), 303–309.
28. Kinniburgh, D, Anderson, RA, Cheng, L, et al. Contraceptive potential of oral desogestrel with depot testosterone in men. International Journal of Obstetrics and Gynaecology, 70, 2000 abstr. FCI/22.05.
29. Laurikka-Routti, M, Haukkamaa, M, Heikinheimo, O, A contraceptive vaginal ring releasing ethinylestradiol and the progestin ST1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 42 (1990), 111–120.
30. Lohiya, NK, Manivannan, B, Mishra, PK, Repeated vas occlusion and non-invasive reversal with styrene maleic anhydride for male contraception in langur monkeys. International Journal of Andrology 23 (2000), 36–42.
31. Liu, X, Li, S, Vasal sterilization in China. Contraception 48 (1993), 255–265.
32. Lue, Y, Sinha Hikim, AP, Wang, C, et al. Triptolide: a potential male contraceptive. Journal of Andrology 19 (1998), 479–486.
33. Massai, R, Miranda, P, Valdes, P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 60 (1999), 9–14.
34. Mertens, W, Evaluation Report on the Emergency Contraception Consortium (revised), 1999, Management Services for Health, Boston, MA, USA.
35. Nityanand, S, Chandrawati, Singh, L, et al. Clinical evaluation of Centchroman: a new oral contraceptive. Puri, CP, Van Look, PFA, (eds.) Hormone Antagonists for Fertility Regulation, 1990, ISSRF, Bombay, India, 223–230.
36. Olsson, SE, Odlind, V, Contraception with a vaginal ring releasing 3-keto-desogestrel and ethinyl estradiol. Contraception 42 (1990), 563–572.
37. Pangkahila, W, Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. International Journal of Andrology 14 (1991), 248–256.
38. Population Division (Department of Economic and Social Affairs, United Nations), World Contraceptive Use in 1998, 1999, United Nations, New York, USA, 261 (document ST/ESA/SER.A/175).
39. Robey, B, Ross, J, Bhushan, I, Meeting Unmet Need: New Strategies. Population Reports, J-43, 1996, 36.
40. Rosenberg, M, Waugh, MS, Solomon, HM, et al. The male polyurethane condom: a review of current knowledge. Contraception 53 (1996), 141–146.
41. Schindler, AE, The 3-keto-desogestrel/ethinylestradiol ring: a new parenteral form of hormonal contraception. European Journal of Obstetrics, Gynecology and Reproductive Biology 49 (1993), 13–14.
42. Shah, I, Perspectives of users and potential users on methods of fertility regulation. Puri, CP, Van Look, PFA, (eds.) Sexual and Reproductive Health. Recent Advances, Future Directions, Vol. II, 2000, New Age International Limited Publishers, New Dehli, India, 45–91.
43. Sitruk-Ware, R, Transdermal application of steroid hormones for contraception. Journal of Steroid Biochemistry & Molecular Biology 53 (1995), 247–251.
44. Soebadi, DM, Gardjito, W, Mensink, HJ, Intravasal injection of formed-in-place medical grade silicone rubber for vas occlusion. International Journal of Andrology 18:suppl. 1 (1995), 45–52.
45. Sundaram, K, Kumar, N, 7-alpha-Methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. International Journal of Andrology 23 (2000), 13–15.
46. Task Force on Long-acting Systemic Agents for Fertility Regulation, United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank (WB), Special Programme of Research, Development and Research Training in Human Reproduction. A randomised comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 62 (2000), 93–99.
47. Task Force on Post-ovulatory Methods of Fertility Regulation, Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 352 (1998), 428–433.
48. Task Force on Post-ovulatory Methods of Fertility Regulation, Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 353 (1999), 697–702.
49. The Population Council and International Family Health, The Case for Microbicides: A Global Priority, 2000, 27.
50. Timmer, CJ, Mulders, TM, Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clinical Pharmacokinetics 39 (2000), 233–242.
51. Trussell, J, Ellertson, C, Stewart, F, The effectiveness of the Yuzpe regimen of postcoital contraception. Family Planning Perspectives 28 (1996), 58–64 87.
52. UNAIDS - Joint United Nations Programme on HIV/AIDS 1999 AIDS epidemic update: December 1999. Document UNAIDS/99.53, pp. 24.
53. Van Look, PFA, Postcoital contraception. Outlook 8 (1990), 2–6.
54. Wallace, EM, Gow, SM, Wu, FCW, Comparison between testosterone enantate-induced azoospermia and oligozoospermia in a male contraceptive study I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol and inhibin concentrations. Journal of Clinical Endocrinology and Metabolism 77 (1993), 290–293.
55. WHO: Task Force on Methods for the Regulation of Male Fertility, Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336 (1990), 955–959.
56. WHO: Task Force on Methods for the Regulation of Male Fertility, Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertility and Sterility 60 (1993), 1062–1068.
57. WHO: Task Force on Methods for the Regulation of Male Fertility, Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertility and Sterility 65 (1996), 821–829.
58. WHO: Division of Reproductive Health (Technical Support) 1997 Unsafe abortion - Global and regional estimates of incidence of and mortality due to unsafe abortion with a listing of available country data. Third Edition [WHO/RHT/MSM/97.16] pp. 109.
59. WHO: Department of Reproductive Health and Research 2000 Annual Technical Report 1999. Document WHO/RHR/00.9, 357.
60. WHO 2001a Maternal mortality in 1995. Estimates developed by WHO, UNICEF and UNFPA. Document WHO/RHR/01.9.
61. WHO 2001b Global prevalence and incidence of selected curable sexually transmitted infections. Document WHO/HIV_AIDS/2001.02, pp. 42.
62. Wildemeersch, D, Schacht, E, Contraception with a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: a pilot study. European Journal of Contraception and Reproductive Health Care, 2001 In press.
63. Wildemeersch, D, Batar, I, Webb, A, et al. GyneFix¯. The frameless intrauterine contraceptive implant for interval, emergency and post-abortal contraception - an update. British Journal of Family Planning 24 (1999), 149–159.
64. Wu, FCW, Farley, TMM, Peregoudov, A, et al. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertility and Sterility 65 (1996), 626–636.
65. Wu, FCW, Balasubramanian, R, Mulders, TMT, et al. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis and lipid metabolism. Journal of Clinical Endocrinology and Metabolism 84 (1999), 112–122.
66. Yuzpe, AA, Lancee, WJ, Ethinyl estradiol and dl-norgestrel as a postcoital contraceptive. Fertility and Sterility 28 (1977), 932–936.
67. Yuzpe, AA, Smith, RP, Rademaker, AW, A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as a postcoital contraceptive agent. Fertility and Sterility 37 (1982), 508–513.
68. Zhang, GY, Gu, YQ, Wang, XH, et al. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. Journal of Clinical Endocrinology and Metabolism 84 (1999), 3642–3647.